FluoroPharma Medical, Inc. (OTCMKTS:FPMI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01.
itself and each of its successors and assigns, waived its
Preferred Ratchet Rights and Warrant Ratchet Rights with respect
to the Subsequent Financing; provided, however, that such waiver
shall be automatically revoked and of no further force and effect
if the Subsequent Financing is not completed by August 10, 2017.
reasonable discretion, to exchange the Preferred Shares then held
by it, valued at their stated value, together with accrued but
unpaid dividends, for securities issued or to be issued in the
Subsequent Financing, if the Company enters into any Subsequent
Financing on terms more favorable than the terms governing the
sale of the Preferred Stock.
term of the Warrant, in the event the Company shall issue any
Additional Shares of Common Stock or Convertible Securities at a
price per share less than the Exercise Price then in effect or
without consideration, then the Exercise Price upon each such
issuance shall be adjusted to the price equal to the
consideration per share paid for such Additional Shares of Common
Stock or Convertible Securities.
Financing, on terms more favorable than the terms governing the
sale of the Preferred Stock under the Purchase Agreement, to
which it may issue Additional Shares of Common Stock or
Convertible Securities at a price per share less than the
Exercise Price in the Warrant .
incorporated in its entirety under this Item 3.03.
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
as a director.Mr. Atinsky was on the audit committee of the Board
of Directors and the compensation committee of the Board of
Directors at the time of his resignation.
Form 8-K as of the date of this Current Report and has been
provided the opportunity to furnish to the Company as promptly as
possible a letter addressed to the Company stating whether he
agrees with the statements made by the Company in this Current
Report, and if not, stating the respects in which he does not
agree. The Company will file any such letter, if it is received
from Mr. Atinsky, within two business days of receipt.
|
Exhibit No.
|
Description
|
|
|
10.1
|
Waiver
|
About FluoroPharma Medical, Inc. (OTCMKTS:FPMI)
FluoroPharma Medical, Inc., formerly Commercial E-Waste Management Inc., is a biopharmaceutical company specializing in discovering, developing and commercializing molecular imaging pharmaceuticals with applications in the area of cardiology. The Company operates through biopharmaceutical research and development segment. It is focused on the development of cardiovascular imaging agents that can detect and assess acute and chronic forms of coronary artery disease (CAD). It has two clinical-stage molecular imaging pharmaceutical product candidates: Flourine-18 (18-F) TPP (BFPET), which includes a ((18F)-labeled cationic lipophilic tetraphenylphosphonium ion (18-F TPP) as an imaging agent designed for use in stress-testing for patients with presumptive or proven CAD, and 18-F FCPHA (CardioPET), which includes Trans-9-(18F)-Fluoro-3, 4-Methyleneheptadecanoic Acid (18-F FCPHA) as a molecular imaging agent designed to assess myocardial blood flow and metabolism in patients with CAD. FluoroPharma Medical, Inc. (OTCMKTS:FPMI) Recent Trading Information
FluoroPharma Medical, Inc. (OTCMKTS:FPMI) closed its last trading session down -0.0180 at 0.0900 with shares trading hands.
